EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieÄquivalenzstudieOpen Access · CC BY-NC-ND 4.0

Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study

Lars Iversen, Curdin Conrad iD, Liv Eidsmo, Antonio Costanzo iD, Joanna Narbutt, Andreas Pinter iD, Külli Kingo, Raquel Rivera Diaz iD, Frank Kolbinger, ManikPrabhu Nanna, Jennifer Annika Frueh, Piotr Jagiello

Journal of the European Academy of Dermatology and Venereology · 2023-05 · 37 (5) · 1004-1016

DOI: 10.1111/jdv.18846 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, online erschienen am 27.01.2023. Verfasst von Lars Iversen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark. Hauptthemen laut MEDLINE: Ultraviolet Therapy, Psoriasis, Biological Products. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologic treatments have been studied mainly in patients with a long‐term history of psoriasis and previous treatment failures.

Objectives

The purpose of this primary analysis of the STEPIn study is to determine whether early intervention with secukinumab in patients with new‐onset moderate to severe plaque psoriasis is superior to standard of care treatment with narrow band ultraviolet B (nb‐UVB) phototherapy.

Methods

The STEPIn study is a randomized, open‐label, multicentre study to investigate early intervention with 52 weeks of secukinumab 300 mg administered subcutaneously versus standard treatment with nb‐UVB phototherapy in patients with new‐onset (≤12 months) moderate to severe plaque psoriasis (NCT03020199). The primary and additional secondary endpoints were ≥90% improvement in Psoriasis Area and Severity Index (PASI 90) at Week 52 and Investigator's Global Assessment (IGA mod 2011) 0/1 response at Week 52, respectively.

Results

In the secukinumab and nb‐UVB study arms, 77/80 and 76/80 randomized patients received at least one dose of study treatment, respectively. The primary endpoint was achieved: 91.1% (70/77) of patients achieved a PASI 90 response at Week 52 in the secukinumab arm versus 42.3% (32/76) in the nb‐UVB arm ( p < 0.0001, odds ratio [OR] estimate [95% confidence intervals, CI] = 16.3 [5.6, 46.9]). The additional secondary endpoint was also achieved: 85.7% of patients achieved an IGA 0/1 response at Week 52 in the secukinumab arm versus 36.8% in the nb‐UVB arm ( p < 0.0001). The safety data were consistent with the safety profiles of secukinumab and nb‐UVB with no new or unexpected safety signals.

Conclusions

Secukinumab was superior to nb‐UVB in treating patients with new‐onset moderate to severe plaque psoriasis. The high and sustained skin clearance observed indicates that biologic treatment for psoriasis may be more effective if used early in the disease course.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ultraviolet TherapyPsoriasisBiological ProductsHumansTreatment OutcomeSeverity of Illness IndexImmunoglobulin AAntibodies, Monoclonal, Humanized

Substanzen

Biological ProductsImmunoglobulin AsecukinumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology and Venereology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Dermatology, CHUV University Hospital and University of Lausanne (UNIL), Lausanne, Switzerland.
  • Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Unit of Rheumatology, Karolinska University Hospital, Stockholm, Sweden.
  • Leo Foundation Skin Immunology Research Center, University of Copenhagen, Copenhagen, Denmark.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.

ORCID-Profile: Curdin Conrad, Antonio Costanzo, Andreas Pinter, Raquel Rivera Diaz

Förderung

  • Novartis Pharma

Zitieren

APA

Iversen, L., Conrad, C., Eidsmo, L., Costanzo, A., Narbutt, J., Pinter, A., Kingo, K., Rivera Diaz, R., Kolbinger, F., Nanna, M., Frueh, J. A., & Jagiello, P. (2023). Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study. Journal of the European Academy of Dermatology and Venereology, 37(5), 1004-1016. https://doi.org/10.1111/jdv.18846

Vancouver

Iversen L, Conrad C, Eidsmo L, Costanzo A, Narbutt J, Pinter A, et al. Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study. Journal of the European Academy of Dermatology and Venereology. 2023;37(5):1004-1016. doi:10.1111/jdv.18846

BibTeX
@article{Iversen2023,
  author = {Iversen, Lars and Conrad, Curdin and Eidsmo, Liv and Costanzo, Antonio and Narbutt, Joanna and Pinter, Andreas and Kingo, Külli and Rivera Diaz, Raquel and Kolbinger, Frank and Nanna, ManikPrabhu and Frueh, Jennifer Annika and Jagiello, Piotr},
  title = {Secukinumab demonstrates superiority over narrow‐band ultraviolet B phototherapy in new‐onset moderate to severe plaque psoriasis patients: Week 52 results from the STEPIn study},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  volume = {37},
  number = {5},
  pages = {1004--1016},
  doi = {10.1111/jdv.18846}
}
Kostenlos starten →